332 related articles for article (PubMed ID: 28887710)
1. Increased mortality in patients with adrenal incidentalomas and autonomous cortisol secretion: a 13-year retrospective study from one center.
Patrova J; Kjellman M; Wahrenberg H; Falhammar H
Endocrine; 2017 Nov; 58(2):267-275. PubMed ID: 28887710
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular events and mortality in patients with adrenal incidentalomas that are either non-secreting or associated with intermediate phenotype or subclinical Cushing's syndrome: a 15-year retrospective study.
Di Dalmazi G; Vicennati V; Garelli S; Casadio E; Rinaldi E; Giampalma E; Mosconi C; Golfieri R; Paccapelo A; Pagotto U; Pasquali R
Lancet Diabetes Endocrinol; 2014 May; 2(5):396-405. PubMed ID: 24795253
[TBL] [Abstract][Full Text] [Related]
3. Autonomous cortisol secretion in adrenal incidentalomas and increased visceral fat accumulation during follow-up.
Yener S; Baris M; Peker A; Demir O; Ozgen B; Secil M
Clin Endocrinol (Oxf); 2017 Nov; 87(5):425-432. PubMed ID: 28656620
[TBL] [Abstract][Full Text] [Related]
4. Accuracy of the dexamethasone suppression test for the prediction of autonomous cortisol secretion-related comorbidities in adrenal incidentalomas.
Araujo-Castro M; Parra Ramírez P; Robles Lázaro C; García Centeno R; Gracia Gimeno P; Fernández-Ladreda MT; Sampedro Núñez MA; Marazuela M; Escobar-Morreale HF; Valderrabano P
Hormones (Athens); 2021 Dec; 20(4):735-744. PubMed ID: 34273083
[TBL] [Abstract][Full Text] [Related]
5. Age-dependent and sex-dependent disparity in mortality in patients with adrenal incidentalomas and autonomous cortisol secretion: an international, retrospective, cohort study.
Deutschbein T; Reimondo G; Di Dalmazi G; Bancos I; Patrova J; Vassiliadi DA; Nekić AB; Debono M; Lardo P; Ceccato F; Petramala L; Prete A; Chiodini I; Ivović M; Pazaitou-Panayiotou K; Alexandraki KI; Hanzu FA; Loli P; Yener S; Langton K; Spyroglou A; Kocjan T; Zacharieva S; Valdés N; Ambroziak U; Suzuki M; Detomas M; Puglisi S; Tucci L; Delivanis DA; Margaritopoulos D; Dusek T; Maggio R; Scaroni C; Concistrè A; Ronchi CL; Altieri B; Mosconi C; Diamantopoulos A; Iñiguez-Ariza NM; Vicennati V; Pia A; Kroiss M; Kaltsas G; Chrisoulidou A; Marina LV; Morelli V; Arlt W; Letizia C; Boscaro M; Stigliano A; Kastelan D; Tsagarakis S; Athimulam S; Pagotto U; Maeder U; Falhammar H; Newell-Price J; Terzolo M; Fassnacht M
Lancet Diabetes Endocrinol; 2022 Jul; 10(7):499-508. PubMed ID: 35533704
[TBL] [Abstract][Full Text] [Related]
6. Predictive model for autonomous cortisol secretion development in non-functioning adrenal incidentalomas.
Araujo-Castro M; García Cano AM; Escobar-Morreale HF; Valderrabano P
Hormones (Athens); 2023 Mar; 22(1):51-59. PubMed ID: 36279032
[TBL] [Abstract][Full Text] [Related]
7. Preclinical Cushing's syndrome in adrenal "incidentalomas": comparison with adrenal Cushing's syndrome.
Reincke M; Nieke J; Krestin GP; Saeger W; Allolio B; Winkelmann W
J Clin Endocrinol Metab; 1992 Sep; 75(3):826-32. PubMed ID: 1517373
[TBL] [Abstract][Full Text] [Related]
8. Maximum adenoma diameter, regardless of uni- or bilaterality, is a risk factor for autonomous cortisol secretion in adrenal incidentalomas.
Araujo-Castro M; Robles Lázaro C; Parra Ramírez P; García Centeno R; Gracia Gimeno P; Fernández-Ladreda MT; Sampedro Núñez MA; Marazuela M; Escobar-Morreale HF; Valderrabano P
J Endocrinol Invest; 2021 Nov; 44(11):2349-2357. PubMed ID: 33683661
[TBL] [Abstract][Full Text] [Related]
9. Pros and cons of dexamethasone suppression test for screening of subclinical Cushing's syndrome in patients with adrenal incidentalomas.
Reimondo G; Allasino B; Bovio S; Saba L; Ardito A; Angeli A; Terzolo M
J Endocrinol Invest; 2011 Jan; 34(1):e1-5. PubMed ID: 20634637
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous assay of cortisol and dexamethasone improved diagnostic accuracy of the dexamethasone suppression test.
Ueland GÅ; Methlie P; Kellmann R; Bjørgaas M; Åsvold BO; Thorstensen K; Kelp O; Thordarson HB; Mellgren G; Løvås K; Husebye ES
Eur J Endocrinol; 2017 Jun; 176(6):705-713. PubMed ID: 28298353
[TBL] [Abstract][Full Text] [Related]
11. Clinical course of patients with adrenal incidentalomas and cortisol autonomy: a German retrospective single center cohort study.
Remde H; Kranz S; Morell SM; Altieri B; Kroiss M; Detomas M; Fassnacht M; Deutschbein T
Front Endocrinol (Lausanne); 2023; 14():1123132. PubMed ID: 37223045
[TBL] [Abstract][Full Text] [Related]
12. Is the 1mg-dexamethasone suppression test a precise marker of glucocorticoid excess and cardiometabolic risk in patients with adrenal incidentalomas?
Araujo-Castro M; Hanzu FA; Pascual-Corrales E; García Cano AM; Marchan M; Escobar-Morreale HF; Valderrabano P; Casals G
Endocrine; 2023 Oct; 82(1):161-170. PubMed ID: 37351760
[TBL] [Abstract][Full Text] [Related]
13. Clinical features, risk of mass enlargement, and development of endocrine hyperfunction in patients with adrenal incidentalomas: a long-term follow-up study.
Falcetta P; Orsolini F; Benelli E; Agretti P; Vitti P; Di Cosmo C; Tonacchera M
Endocrine; 2021 Jan; 71(1):178-188. PubMed ID: 32915435
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of GH reserve in patients with adrenal incidentalomas and biochemical evidence of subclinical autonomous glucocorticoid hypersecretion.
Tzanela M; Zianni D; Stylianidou Ch; Karavitaki N; Tsagarakis S; Thalassinos NC
Clin Endocrinol (Oxf); 2005 May; 62(5):597-602. PubMed ID: 15853831
[TBL] [Abstract][Full Text] [Related]
15. Cardiometabolic profile of non-functioning and autonomous cortisol-secreting adrenal incidentalomas. Is the cardiometabolic risk similar or are there differences?
Araujo-Castro M; Robles Lázaro C; Parra Ramírez P; Cuesta Hernández M; Sampedro Núñez MA; Marazuela M
Endocrine; 2019 Dec; 66(3):650-659. PubMed ID: 31473918
[TBL] [Abstract][Full Text] [Related]
16. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors.
Fassnacht M; Arlt W; Bancos I; Dralle H; Newell-Price J; Sahdev A; Tabarin A; Terzolo M; Tsagarakis S; Dekkers OM
Eur J Endocrinol; 2016 Aug; 175(2):G1-G34. PubMed ID: 27390021
[TBL] [Abstract][Full Text] [Related]
17. Association Between Mortality and Levels of Autonomous Cortisol Secretion by Adrenal Incidentalomas : A Cohort Study.
Kjellbom A; Lindgren O; Puvaneswaralingam S; Löndahl M; Olsen H
Ann Intern Med; 2021 Aug; 174(8):1041-1049. PubMed ID: 34029490
[TBL] [Abstract][Full Text] [Related]
18. Saliva versus serum cortisol to identify subclinical hypercortisolism in adrenal incidentalomas: simplicity versus accuracy.
Vieira-Correa M; Giorgi RB; Oliveira KC; Hayashi LF; Costa-Barbosa FA; Kater CE
J Endocrinol Invest; 2019 Dec; 42(12):1435-1442. PubMed ID: 31456173
[TBL] [Abstract][Full Text] [Related]
19. Cortisol secretion from adrenal adenomas discovered as incidentalomas is responsive to ACTH.
Olsen H; Olofsson L; Mjöman M
Clin Endocrinol (Oxf); 2014 Mar; 80(3):335-41. PubMed ID: 23865937
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic accuracy of the different hormonal tests used for the diagnosis of autonomous cortisol secretion.
Araujo-Castro M; García Cano A; Jiménez Mendiguchía L; Escobar-Morreale HF; Valderrábano P
Sci Rep; 2021 Oct; 11(1):20539. PubMed ID: 34654835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
